Alaunos Therapeutics completes acquisition of Velaris Therapeutics

Alaunos completed its acquisition of privately held Velaris Therapeutics, adding a pipeline targeting pulmonary arterial hypertension and related cardiopulmonary diseases. The deal brings ActRII-Fc ligand traps and complementary biologics aimed at correcting signaling imbalances linked to pulmonary vascular remodeling. The transaction was disclosed in a Form 8-K filed on Oct. 13, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: NY70405) on October 13, 2026, and is solely responsible for the information contained therein. (C)